Oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
AssigneeUniversity of Central Florida Research Foundation, Inc.
InventorsGriffith Parks, Alicja Copik
Life of this patent
Estimating the term…
Abstract
Disclosed are engineered oncolytic viruses, related fusion proteins and polynucleotides encoding them, and methods for treating cancer using the engineered viruses. In one aspect, disclosed herein are engineered oncolytic viruses, wherein the oncolytic virus expresses one or more exogenous membrane bound immune cell targeting ligands comprising an uncleaved signal anchor.
Claims27
An engineered oncolytic virus wherein the oncolytic virus expresses one or more exogenous membrane bound immune cell targeting ligands comprising an uncleaved signal anchor, wherein the one or more exogenous membrane bound immune cell targeting ligands comprise an immunoglobulin Fc domain modified to have an inverted orientation with its amino terminal end facing intracellularly.
A fusion protein comprising an uncleaved signal anchor domain comprising:
- a cytoplasmic tail region, a transmembrane region and an extracellular stalk region;
- and an immunoglobulin Fc domain modified to have an inverted orientation with its amino terminal end facing intracellularly and wherein the amino terminal end of the immunoglobulin Fc domain is fused to a C-terminus of the extracellular stalk region.
Dependencies are inferred from the claim text.